Less cholesterol means better tumor killing for cytotoxic T9 cells by Griesenauer, Brad & Paczesny, Sophie
INSIGHTS
Rockefeller University Press https://doi.org/10.1084/jem.20180852 1505
J. Exp. Med. 2018 Vol. 215 No. 6 1505–1506
In this issue, Ma et al. (https:// doi .org/ 10 .1084/ jem .20171576) show that removal of cholesterol from CD8 T cells during type 9 
differentiation increases their IL-9 production, persistence in vivo, and cytolytic function against tumors by preventing 
SUMOylation of liver X receptors.
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Ma et al. (2018) show that cholesterol neg-
atively regulates differentiation of CD8 T 
cells toward a type 9 phenotype through 
SUMOylation of liver X receptors (LXRs) 
and that removal of cholesterol from these 
cells increases their IL-9 production and an-
titumor activity. IL-9–producing cytotoxic 
CD8 T cells (Tc9) have been shown to have 
better tumor killing potential than the clas-
sical IFN-γ–producing cytotoxic CD8 T cells 
(Tc1) in several studies and with different 
tumor models (melanoma, lung metastasis, 
lymphoma, and acute myeloid leukemia; 
Lu et al., 2012, 2014; Purwar et al., 2012; 
Ramadan et al., 2017; Ma et al., 2018).
Cancer immunotherapy was designated 
as the “breakthrough therapy” of the year 
in 2013 by Science, and for good reason. 
These therapies allow a person’s own im-
mune cells, often T cells, to specifically 
target tumor cells while limiting normal 
tissue damage. Use of antibodies against 
the checkpoint molecules programmed cell 
death protein 1 and cytotoxic T-lymphocyte 
antigen 4, which tumors use to normally 
inhibit the immune response, increase the 
antitumor activity of T cells across multiple 
malignancies mediated primarily through 
CD8 T cells (Topalian et al., 2012; Eggermont 
et al., 2016). Cancer vaccines have been 
made from neoantigens from cancer cells 
to help target T cells against the cancer (Ott 
et al., 2017). Adoptive transfer of manipu-
lated T cells through generation of chime-
ric antigen receptors has shown incredible 
promise against blood cancers and have now 
received Food and Drug Administration ap-
proval (Maude et al., 2014; Neelapu et al., 
2017). Now, the group of Qing Yi and col-
leagues (see Ma et al. in this issue) report 
that Tc9 cells differentiated with minimal 
cholesterol increases their persistence and 
increases their antitumor activity in vivo.
Cholesterol is important for membrane 
protein function, regulating transmem-
brane signaling, and membrane trafficking, 
while also acting as a metabolite for signal 
transduction. In T cells, cholesterol can 
influence TCR signaling, immunological 
synapse formation, and cytokine secretion, 
all of which can influence antitumor activ-
ity (Wang et al., 2016; Yang et al., 2016). To 
identify cholesterol as a negative regulator 
of Tc9 differentiation, Ma et al. (2018) first 
used Ingenuity Pathway Analysis compar-
ing microarrays from murine cytotoxic CD8 
T cells differentiated under type 1 (IL-2 and 
IL-12) and type 9 (TGF-β and IL-4) cytokine 
conditions. They found that Tc9 cells have 
lower basal expression of cholesterol syn-
thesis genes, such as Hmgcr and Sqle, and 
high expression of cholesterol efflux genes, 
such as Abca1 and Abcg1, than Tc1 cells. To 
further characterize how cholesterol affects 
Tc9 cells, they added either cholesterol or 
cholesterol inhibitors like β-cyclodextrin 
(β-CD) and statins drugs to increase or de-
crease, respectively, the amount of choles-
terol in the Tc9 cells. IL-9 expression and 
production, a hallmark of successful Tc9, 
was down-regulated with the addition of 
cholesterol and up-regulated with the ad-
dition of β-CD or statins. Importantly, this 
phenotype was recapitulated in human 
cells. Tc9 cells from Apoe−/− mice, a trans-
genic, atherosclerosis-prone mouse with 
high levels of cellular and plasma choles-
terol, had impaired IL-9 expression and 
production compared with Tc9 cells from 
wild-type mice. The authors found that the 
cholesterol-mediated regulation of IL-9 is 
specifically dependent on LXRs because all 
oxysterols but no other cholesterol deriva-
tives inhibited IL-9 expression and secre-
tion, further suggesting the inhibitory role 
of LXRs on IL-9 production. Synthetic LXR 
agonists also inhibited IL-9 production in 
Tc9 cells. Indeed, cholesterol and oxysterols 
cause SUMOylation of LXRs, leading to inhi-
bition of IL-9 through reducing the binding 
of the transcription factor p65 to the Il9 pro-
moter in the Tc9 cells.
Type 9 cells have been shown to persist 
long term in vivo after transfer in multiple 
studies (Lu et al., 2012, 2014; Ramadan et al., 
2017). Ma et al. (2018) show here that Tc9 
cells from Pmel-1 mice, a transgenic strain 
that carries a rearranged T cell receptor spe-
cific for pmel-17, an orthologue of the mela-
nocyte differentiation antigen gp100, which 
is overexpressed in many human mela-
nomas, persist longer than Tc1 cells when 
adoptively transferred into MC38-gp100 
tumor bearing mice. Treatment of Tc9 
cells with β-CD before adoptive transfer in-
creased their persistence in vivo, whereas 
treatment with cholesterol decreased their 
persistence compared with untreated Tc9 
cells by decreasing and increasing apop-
tosis, respectively. Importantly, treatment 
with β-CD increased the number of IFN-γ 
and granzyme-B–producing Tc9 cells in 
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the tumor, which are required for optimal 
tumor killing. This led to decreased tumor 
growth both in this skin tumor model and 
in a metastatic lung tumor model. Surpris-
ingly, the cholesterol level in the hosts did 
not affect the killing potential of the adop-
tively transferred Tc9 cells, as tumors in 
Apoe−/− hosts grew similarly to tumors in 
wild-type hosts when both were treated 
with β-CD-Tc9 cells. The antitumor activity 
of these cells is strongly dependent on IL-9 
expression, as loss of IL-9 led to poor per-
sistence and poor antitumor activity. These 
effects are summarized in the figure.
One of the more interesting data Ma et al. 
(2018) received from their microarray study 
was the increase in Il1rl1 expression. Il1rl1 en-
codes for the protein ST2, also known as the 
IL-33 receptor. It has recently been shown 
that adding IL-33 to normal type 9 differen-
tiation promotes IL-9 production and ST2 
expression on their cell surface. In mice 
with lymphoma or acute myeloid leukemia, 
these type 9 T cells with IL-33 (T9IL-33), when 
adoptively transferred into mice undergoing 
allogeneic bone marrow transplantation, ex-
hibited a stronger antitumor effect than T9 
cells without IL-33 (Ramadan et al., 2017). It 
would be exciting to see if removing choles-
terol during in vitro differentiation or with 
systemic administration of statins along with 
addition of IL-33 could further increase the 
antitumor potential of these T cells. In addi-
tion, IL-9 seems to be a driver of antitumor 
activity of these cells, as loss of IL-9 abrogated 
the effects of β-CD and IL-33 (Ramadan et al., 
2017; Ma et al., 2018). What role IL-9 has in 
promoting antitumor activity has yet to be 
elucidated. It is important that we now try to 
understand why IL-9 is necessary for optimal 
type 9 T cell antitumor function so that we 
may bring this type of adoptive transfer ther-
apy closer to the clinic.
The results presented by the authors con-
trast the data showing that increased free 
cholesterol content in cells through inhibi-
tion of cholesterol esterification enhances 
the antitumor activity of CD8 T cells (Yang 
et al., 2016). Whereas bulk CD8 cells may re-
quire more cholesterol for their antitumor 
effect, cholesterol has been shown in vari-
ous cell lines to negatively modulate TGF-β 
signaling, which is necessary for type 9 T 
cells (Chen et al., 2007). Together, these data 
suggest that cholesterol and TGF-β may have 
contrasting functions for Tc9 cell differenti-
ation and function.
There are important clinical implica-
tions on modulating cholesterol during T 
cell culture for adoptive transfer. Although 
over 70% of American adults are at least 
overweight and almost 38% are obese (Fryar 
et al., 2016), treatment of overweight or 
obese patients with adoptively transferred 
Tc9 cells differentiated with minimal cho-
lesterol may not be affected, as suggested 
by the experiments by Ma et al. (2018) that 
show that wild-type Tc9 cells adoptively 
transferred into Apoe−/− hosts have simi-
lar antitumor activity as when transferred 
into wild-type hosts. However, an import-
ant caveat of these experiments is that the 
adoptively transferred T cells were specific 
for the tumor antigen. It would be of inter-
est to repeat these experiments using bulk 
Tc9 cells treated with β-CD or statins that 
are already used in clinic. Many patients 
who are overweight or obese also have high 
cholesterol and they are treated with statins 
to help reduce their cholesterol. Statins 
have already been shown to be effective 
in enhancing antitumor activity through 
exerting anti-proliferative, proapoptotic, 
and anti-invasive effects of the tumor it-
self (Altwairgi, 2015). Perhaps, statins also 
increase IL-9 production in T cells, which 
could further explain the antitumor effect 
seen in patients who take statins. Adoptive 
transfer of both CD4 and CD8 T cells differ-
entiated under type 9 conditioning has also 
recently been shown to better control lym-
phoma and acute myeloid leukemia after 
experimental bone marrow transplantation 
(Ramadan et al., 2017). It will be of interest 
to determine if adoptive transfer of T cells 
differentiated under type 9 conditioning 
can increase antitumor activity against 
other tumor types besides melanoma, lung 
metastasis, lymphoma, and acute myeloid 
leukemia. Collectively, the results of this 
study along with what is known about the 
antitumor capabilities of Tc9 cells will lead 
to more exciting research toward develop-
ment of better adoptive transfer therapies 
against tumors.
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Effect of cholesterol on antitumor activity of Tc9 
cells. Left: Differentiation of Tc9 cells with low 
cholesterol decreases the SUMOylation of LXRs, 
leading to increased production of the cytolytic 
proteins IFN-γ and Gzmb, increased IL-9 production, 
possibly increased IL-9R expression, and increased 
expression of ST2. These cells have strong 
antitumor activity. Right: Differentiation of Tc9 cells 
with high cholesterol increases the SUMOylation 
of LXRs, leading to decreased production of the 
cytolytic proteins IFN-γ and Gzmb, decreased IL-9 
production, possibly decreased IL-9R expression, 
and decreased expression of ST2. These cells have 
weak antitumor activity.
